Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer?

The aim of this pilot study was to assess the role of immune markers in fast relapse (<2 years) of high-grade muscle invasive urothelial carcinomas of the bladder (HGUC) treated by cystectomy. A series of 40 such cases was investigated for immune protein (CD3, CD4, CD8, CD20, CD68, CD163, FOXP3 and PD-1) status by immunohistochemistry.

Decreased expression of all immune cell markers was observed in tumors of patients who relapsed quickly. In Kaplan-Meier (log-rank test) analysis, low CD3, CD4 and CD8 expression was associated with fast relapse (P = 0.005, 0.028, 0.036 respectively). Additional evaluation of the immune transcriptome by NanoString Human PanCancer Immune Panel v.1.1 has identified 5 differentially expressed genes significantly associated with fast relapse. Among these, KLRB1 and HLA-DQA1 were also significant on Kaplan-Meier analysis (log-rank test P = 0.007 and 0.006, respectively). These findings strengthen the potential clinical utility and, hence, the need for further evaluation of immune markers in HGUC prognostication.

Pathology, research and practice. 2020 Sep 05 [Epub ahead of print]

Ekaterina Olkhov-Mitsel, Anjelica Hodgson, Stanley K Liu, Danny Vesprini, Jane Bayani, John M S Bartlett, Bin Xu, Michelle R Downes

Division of Anatomic Pathology, Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Division of Anatomic Pathology, Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada., Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Diagnostic Development, Ontario Institute for Cancer Research, Toronto, ON, Canada., Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Diagnostic Development, Ontario Institute for Cancer Research, Toronto, ON, Canada., Pathology, Memorial Sloan Kettering Cancer Center, New York City, NK, USA., Division of Anatomic Pathology, Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Electronic address: .

Go Beyond the Abstract and Read a Commentary by the Authors